If it delivers on the promise suggested by preclinical research, it would represent a meaningful addition to GERD treatment options
Across in-vitro and in-vivo models, investigators have used GHK-Cu to examine wound repair, ECM turnover, oxidative stress responses, and neuro-related endpoints by measuring readouts such as collagen deposition, inflammatory markers, vascular responses, and gene-expression profiles
Campelo and Malhotra, 2012
AOD-9604: Direct Lipolysis Theory AOD-9604 is a modified C-terminal fragment of human growth hormone, designed to isolate GH's fat-metabolizing properties: Lipolysis Activation: Theorized to stimulate fat breakdown through beta-3 adrenergic receptor pathways No IGF-1 Stimulation: Unlike full GH, AOD-9604 does not elevate insulin-like growth factor 1 Non-diabetogenic: Does not impair glucose metabolism or insulin sensitivity No Anabolic Effects: Does not promote muscle or organ growth Semaglutide: Central Regulation Theory Semaglutide achieves weight loss through systemic metabolic regulation: Hypothalamic Appetite Control: GLP-1 receptors in the brain reduce hunger and food-seeking behavior Gastric Emptying: Slowed stomach emptying promotes early satiety Insulin Optimization: Glucose-dependent insulin secretion improves metabolic efficiency Reward Pathway Modulation: Reduced hedonic eating and food reward responses The fundamental difference: AOD-9604 attempts to "burn" existing fat directly, while Semaglutide reduces caloric intake through appetite and satiety mechanisms, creating an energy deficit that leads to fat loss
I would recommend this product because it is WONDERFUL
